The global Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors market is expected to grow at a CAGR of around 8.5% during the forecast period, from 2021 to 2030. The growth in this market is attributed to the increasing prevalence of type 2 diabetes and obesity, which are major risk factors for cardiovascular diseases and kidney disease.
The global Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin). On the basis of application, it is segmented into hospital and medical research institute. On the basis of region, it is segmented into North America, Latin America, Europe, Asia Pacific and Middle East & Africa.
- Increasing prevalence of type-2 diabetes and obesity are driving the growth of the Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market.
- The increasing number of people suffering from type-2 diabetes and obesity is also driving the growth of this market, as these conditions are associated with increased risk for cardiovascular diseases, which in turn increases demand for Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors drugs to manage blood sugar levels in patients with these conditions.
- Increasing awareness about lifestyle changes that can help prevent or delay type-2 diabetes and obesity is also driving the growth of this market.
- The high cost associated with treatment options for type-2 diabetes and obesity is a major factor restraining the growth of this market.
Industry Growth Insights published a new data on “Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market”. The research report is titled “Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market research by Types (Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin)), By Applications (Hospital, Medical Research Institute, Other), By Players/Companies Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb, Kotobuki Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Research Report
By Type
Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin)
By Application
Hospital, Medical Research Institute, Other
By Companies
Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb, Kotobuki Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
 Inhibitors Industry Outlook.svg)
Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Report Segments:
The global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors market is segmented on the basis of:
Types
Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Medical Research Institute, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Janssen Pharmaceuticals
- Astellas
- Boehringer Ingelheim
- AstraZeneca
- Bristol Myers Squibb
- Kotobuki Pharmaceutical
 Inhibitors Market Overview.svg)
Highlights of The Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Farxiga/Forxiga (Dapagliflozin)
- Suglat (Ipragliflozin)
- By Application:
- Hospital
- Medical Research Institute
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitors Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
SGLT 2 inhibitors are medications that block the transport of glucose across the blood-brain barrier. This can lead to decreased blood sugar levels in people with diabetes, and may also help prevent seizures in people with epilepsy.
Some of the major companies in the sodium/glucose cotransporter 2 (sglt 2) inhibitors market are Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb, Kotobuki Pharmaceutical.
The sodium/glucose cotransporter 2 (sglt 2) inhibitors market is expected to grow at a compound annual growth rate of 8.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market - Supply Chain
4.5. Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Forecast
4.5.1. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Absolute $ Opportunity
5. Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Type
5.3.1. Invokana (Canagliflozin)
5.3.2. Jardiance (Empagliflozin)
5.3.3. Farxiga/Forxiga (Dapagliflozin)
5.3.4. Suglat (Ipragliflozin)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Medical Research Institute
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Demand Share Forecast, 2019-2026
9. North America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Medical Research Institute
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Type
9.7.1. Invokana (Canagliflozin)
9.7.2. Jardiance (Empagliflozin)
9.7.3. Farxiga/Forxiga (Dapagliflozin)
9.7.4. Suglat (Ipragliflozin)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Demand Share Forecast, 2019-2026
10. Latin America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Medical Research Institute
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Type
10.7.1. Invokana (Canagliflozin)
10.7.2. Jardiance (Empagliflozin)
10.7.3. Farxiga/Forxiga (Dapagliflozin)
10.7.4. Suglat (Ipragliflozin)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Demand Share Forecast, 2019-2026
11. Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Medical Research Institute
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Type
11.7.1. Invokana (Canagliflozin)
11.7.2. Jardiance (Empagliflozin)
11.7.3. Farxiga/Forxiga (Dapagliflozin)
11.7.4. Suglat (Ipragliflozin)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Demand Share, 2019-2026
12. Asia Pacific Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Medical Research Institute
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Type
12.7.1. Invokana (Canagliflozin)
12.7.2. Jardiance (Empagliflozin)
12.7.3. Farxiga/Forxiga (Dapagliflozin)
12.7.4. Suglat (Ipragliflozin)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Demand Share, 2019-2026
13. Middle East & Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Medical Research Institute
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size and Volume Forecast by Type
13.7.1. Invokana (Canagliflozin)
13.7.2. Jardiance (Empagliflozin)
13.7.3. Farxiga/Forxiga (Dapagliflozin)
13.7.4. Suglat (Ipragliflozin)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market: Market Share Analysis
14.2. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Distributors and Customers
14.3. Sodium/Glucose Cotransporter 2 (SGLT 2) Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eli Lilly
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Janssen Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Astellas
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Boehringer Ingelheim
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AstraZeneca
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol Myers Squibb
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Kotobuki Pharmaceutical
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
